Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).

Xenon is a clinical-stage drug company, and its lead drug candidate is Azetukalner (formerly XEN1101), a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. Xenon is developing Azetukalner for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder (MDD), and bipolar depression. In January 2025, Xenon announced it initiated its Phase 3 X-NOVA2 trial which would recruit 450 patients and give them the 20-mg dose of Azetukalner to treat MDD.